2023-08-23 11:57:49 ET
- Organovo Holdings ( NASDAQ: ONVO ) is up 4% in Wednesday morning trading after the company said that the first clinical trials for ulcerative colitis FXR314 would begin two years ahead of schedule.
- The original plan was that they would begin in 2025.
- The biopharma said that phase 1 safety data was positive and FXR314 is demonstrating disease effects in a 3D human cellular model of ulcerative colitis.
- The asset is also in phase 2 for nonalcoholic steatohepatitis ( NASH ). Interim data showed FXR314 lowered liver fat content. Full phase 2 data in this indication is expected in H1 2024.
- Organovo ( ONVO ) added that it plans to file Investigational New Drug applications for other candidates in its pipeline starting in 2025
For further details see:
Organovo up 4% as it boosts timeline for ulcerative colitis asset